Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00045994
Status:
COMPLETED
Last Update Posted:
2009-07-29
First Post:
2002-09-17
Brief Title:
The SILVER Study Systolic Hypertension Interaction With Left Ventricular Remodeling
Sponsor:
Synvista Therapeutics Inc
Organization:
Synvista Therapeutics Inc
Study Overview
Official Title:
Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity The SILVER Study
Status:
COMPLETED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal study in patients with left ventricular hypertrophy Eligible patients will be randomized to double-blind treatment once daily for 6 months with oral ALT-711 210 mg or placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None